First American Trust FSB Lowers Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

First American Trust FSB cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 32,846 shares of the medical research company’s stock after selling 726 shares during the period. First American Trust FSB’s holdings in IQVIA were worth $6,455,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in IQV. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the fourth quarter worth about $33,000. Avior Wealth Management LLC increased its position in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the period. Lee Danner & Bass Inc. purchased a new position in shares of IQVIA during the 4th quarter worth approximately $44,000. Zions Bancorporation N.A. lifted its holdings in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after buying an additional 85 shares during the period. Finally, Versant Capital Management Inc boosted its stake in shares of IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after buying an additional 93 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQV opened at $186.35 on Tuesday. The company has a market capitalization of $32.86 billion, a price-to-earnings ratio of 24.85, a PEG ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $179.28 and a 1 year high of $254.54. The company’s 50 day simple moving average is $194.58 and its 200 day simple moving average is $207.73.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on IQV. Barclays reduced their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Bank of America reduced their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Royal Bank of Canada restated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. UBS Group reduced their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.